Compare Stocks: PHIO, MCRB, INMB, and TCRT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
INMB INmune Bio	$1.75 -1.1%	$1.58	$1.09 ▼ $2.96	$46.52M	0.97	662,257 shs	225,746 shs
MCRB Seres Therapeutics	$4.83 +1.0%	$6.44	$4.59 ▼ $29.98	$46.77M	0.2	94,898 shs	51,175 shs
PHIO Phio Pharmaceuticals	$1.03 -0.5%	$1.05	$0.81 ▼ $4.19	$11.91M	0.82	1.55 million shs	93,073 shs
TCRT Alaunos Therapeutics	$1.88	$2.20	$1.67 ▼ $4.59	$45.91M	-1	12,620 shs	9,610 shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
INMB INmune Bio	0.00%	+8.02%	+2.94%	+15.89%	-34.70%
MCRB Seres Therapeutics	0.00%	-2.82%	-37.60%	-36.53%	-66.46%
PHIO Phio Pharmaceuticals	0.00%	-1.44%	+2.50%	-10.09%	-57.82%
TCRT Alaunos Therapeutics	0.00%	-3.09%	-9.62%	-27.97%	-34.49%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
INMB INmune Bio	$1.75 -1.1%	$1.58	$1.09 ▼ $2.96	$46.52M	0.97	662,257 shs	225,746 shs
MCRB Seres Therapeutics	$4.83 +1.0%	$6.44	$4.59 ▼ $29.98	$46.77M	0.2	94,898 shs	51,175 shs
PHIO Phio Pharmaceuticals	$1.03 -0.5%	$1.05	$0.81 ▼ $4.19	$11.91M	0.82	1.55 million shs	93,073 shs
TCRT Alaunos Therapeutics	$1.88	$2.20	$1.67 ▼ $4.59	$45.91M	-1	12,620 shs	9,610 shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
INMB INmune Bio	0.00%	+8.02%	+2.94%	+15.89%	-34.70%
MCRB Seres Therapeutics	0.00%	-2.82%	-37.60%	-36.53%	-66.46%
PHIO Phio Pharmaceuticals	0.00%	-1.44%	+2.50%	-10.09%	-57.82%
TCRT Alaunos Therapeutics	0.00%	-3.09%	-9.62%	-27.97%	-34.49%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
INMB INmune Bio	2.50	Moderate Buy	N/A	N/A
MCRB Seres Therapeutics	2.25	Hold	$17.00	251.97% Upside
PHIO Phio Pharmaceuticals	2.00	Hold	$14.00	1,265.85% Upside
TCRT Alaunos Therapeutics	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest PHIO, MCRB, INMB, and TCRT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/31/2026	TCRT Alaunos Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/20/2026	INMB INmune Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/17/2026	PHIO Phio Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/23/2026	MCRB Seres Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$12.00
6/23/2026	MCRB Seres Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
6/23/2026	MCRB Seres Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$12.00
6/11/2026	INMB INmune Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
5/29/2026	TCRT Alaunos Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
5/18/2026	MCRB Seres Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (D-)
5/15/2026	TCRT Alaunos Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 8/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
INMB INmune Bio	$50K	930.30	N/A	N/A	$0.88 per share	1.99
MCRB Seres Therapeutics	$790K	59.18	$1.09 per share	4.45	$4.89 per share	0.99
PHIO Phio Pharmaceuticals	N/A	N/A	N/A	N/A	$1.87 per share	N/A
TCRT Alaunos Therapeutics	N/A	N/A	N/A	N/A	$0.93 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
INMB INmune Bio	-$45.93M	-$1.67	N/A	N/A	N/A	N/A	-103.03%	-77.66%	8/6/2026 (Estimated)
MCRB Seres Therapeutics	$5.70M	-$5.17	N/A	N/A	N/A	N/A	-130.29%	-35.35%	8/5/2026 (Estimated)
PHIO Phio Pharmaceuticals	-$8.70M	-$1.38	N/A	N/A	N/A	N/A	-77.34%	-70.87%	8/13/2026 (Estimated)
TCRT Alaunos Therapeutics	-$4.18M	-$2.13	N/A	N/A	N/A	N/A	-165.94%	-123.50%	8/18/2026 (Estimated)

Latest PHIO, MCRB, INMB, and TCRT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	PHIO Phio Pharmaceuticals	-$0.36	N/A	N/A	N/A	N/A	N/A
8/6/2026	Q2 2026	INMB INmune Bio	-$0.2067	N/A	N/A	N/A	$1.16 million	N/A
8/5/2026	Q2 2026	MCRB Seres Therapeutics	-$2.1850	N/A	N/A	N/A	$0.18 million	N/A
5/15/2026	Q1 2026	TCRT Alaunos Therapeutics	N/A	-$0.59	N/A	-$0.59	N/A	N/A
5/7/2026	Q1 2026	INMB INmune Bio	-$0.2450	-$0.20	+$0.0450	-$0.20	$1.11 million	N/A
5/7/2026	Q1 2026	PHIO Phio Pharmaceuticals	-$0.24	-$0.34	-$0.10	-$0.34	N/A	N/A
5/5/2026	Q1 2026	MCRB Seres Therapeutics	-$1.88	-$2.08	-$0.20	-$2.08	$0.36 million	$0.36 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
INMB INmune Bio	N/A	N/A	N/A	N/A	N/A
MCRB Seres Therapeutics	N/A	N/A	N/A	N/A	N/A
PHIO Phio Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TCRT Alaunos Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
INMB INmune Bio	N/A	4.24	4.24
MCRB Seres Therapeutics	N/A	1.65	1.65
PHIO Phio Pharmaceuticals	N/A	18.32	18.32
TCRT Alaunos Therapeutics	N/A	1.63	1.63

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
INMB INmune Bio	12.72%
MCRB Seres Therapeutics	59.34%
PHIO Phio Pharmaceuticals	57.31%
TCRT Alaunos Therapeutics	27.72%

Insider Ownership

Company	Insider Ownership
INMB INmune Bio	21.40%
MCRB Seres Therapeutics	5.20%
PHIO Phio Pharmaceuticals	0.89%
TCRT Alaunos Therapeutics	16.14%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
INMB INmune Bio	10	26.58 million	20.90 million	Optionable
MCRB Seres Therapeutics	330	9.68 million	9.18 million	Optionable
PHIO Phio Pharmaceuticals	10	11.62 million	11.51 million	Not Optionable
TCRT Alaunos Therapeutics	40	24.42 million	20.48 million	No Data

PHIO, MCRB, INMB, and TCRT Headlines

Recent News About These Companies

Alaunos Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment for Body Fat Percentage in 48-Day DIO Mouse Study

June 29, 2026 | markets.businessinsider.com

Alaunos Therapeutics, Inc.: Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies

May 26, 2026 | finanznachrichten.de

Alaunos reports positive preclinical obesity drug results across weight, liver, insulin markers

May 26, 2026 | msn.com

Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies

May 26, 2026 | globenewswire.com

Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models

May 18, 2026 | globenewswire.com

Weight Loss Data From Obese Mice Looks Promising For Alaunos Therapeutics, But Shares Drop

March 2, 2026 | benzinga.com

Alaunos Reports Positive Preclinical Data for Obesity Candidate

March 2, 2026 | tipranks.com

Alaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders

March 2, 2026 | globenewswire.com

Alaunos Therapeutics Reaches Settlement With MD Anderson Cancer

December 23, 2025 | tipranks.com

Alaunos Therapeutics files to sell 327,740 shares of common for holders

October 22, 2025 | msn.com

Alaunos Therapeutics files $50M mixed securities shelf

August 21, 2025 | msn.com

Alaunos Therapeutics files $50M mixed securities shelf

August 21, 2025 | msn.com

Alaunos Therapeutics’ Innovative Glioblastoma Study Completes: Market Implications

August 12, 2025 | msn.com

Alaunos Therapeutics Appoints Holger Weis as New CEO

July 25, 2025 | theglobeandmail.com

Alaunos Therapeutics Taps Board Member Weis as Next CEO

July 2, 2025 | marketwatch.com

Alaunos Therapeutics, Inc. (TCRT) - Yahoo Finance

June 26, 2025 | finance.yahoo.com

Alaunos Therapeutics Raises $850,000 in Private Offering

June 26, 2025 | tipranks.com

Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering - Morningstar

June 24, 2025 | morningstar.comM

Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering

June 23, 2025 | globenewswire.com

Alaunos Therapeutics Amends Warrant Agreement with Mast Hill

June 10, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHIO, MCRB, INMB, and TCRT Company Descriptions

INmune Bio NASDAQ:INMB

$1.75 -0.02 (-1.13%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$1.78 +0.03 (+1.49%)

As of 07/31/2026 07:57 PM Eastern

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Seres Therapeutics NASDAQ:MCRB

$4.83 +0.05 (+1.05%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$4.82 -0.01 (-0.21%)

As of 07/31/2026 07:34 PM Eastern

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Phio Pharmaceuticals NASDAQ:PHIO

$1.02 -0.01 (-0.49%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$0.99 -0.04 (-3.51%)

As of 07/31/2026 07:46 PM Eastern

Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.

Alaunos Therapeutics NASDAQ:TCRT

$1.88 0.00 (0.00%)

Closing price 07/31/2026 03:59 PM Eastern

Extended Trading

$1.93 +0.05 (+2.66%)

As of 07/31/2026 04:12 PM Eastern

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PHIO, MCRB, INMB, and TCRT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PHIO, MCRB, INMB, and TCRT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PHIO, MCRB, INMB, and TCRT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHIO, MCRB, INMB, and TCRT Company Descriptions

INmune Bio NASDAQ:INMB

Seres Therapeutics NASDAQ:MCRB

Phio Pharmaceuticals NASDAQ:PHIO

Alaunos Therapeutics NASDAQ:TCRT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PHIO, MCRB, INMB, and TCRT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PHIO, MCRB, INMB, and TCRT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PHIO, MCRB, INMB, and TCRT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHIO, MCRB, INMB, and TCRT Company Descriptions

INmune Bio NASDAQ:INMB

Seres Therapeutics NASDAQ:MCRB

Phio Pharmaceuticals NASDAQ:PHIO

Alaunos Therapeutics NASDAQ:TCRT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools